Total submissions: 10
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000790797 | SCV000232923 | pathogenic | not provided | 2013-09-25 | criteria provided, single submitter | clinical testing | |
IIFP, |
RCV000180473 | SCV000262515 | pathogenic | Mucopolysaccharidosis, MPS-II | 2007-08-02 | criteria provided, single submitter | research | |
Laboratory of Diagnosis and Therapy of Lysosomal Disorders, |
RCV000180473 | SCV000929887 | pathogenic | Mucopolysaccharidosis, MPS-II | 2024-06-07 | criteria provided, single submitter | literature only | In vitro or in vivo functional studies supportive of a damaging effect (PS3_Moderate), Prevalence of the variant significantly increased in affected individuals compared with controls (PS4_Strong), Absent from controls (or at low frequency) in gnomAD database (PM2_Moderate), Cosegregation with disease in multiple affected family members (PP1_Moderate), Missense variant in a gene with a low rate of benign missense variation (PP2_Supporting), Multiple lines of computational evidence support a deleterious effect (PP3_Supporting), Patient’s phenotype or family history highly specific for the disease (PP4_Moderate) |
Department of Medical Genetics, |
RCV000180473 | SCV001480198 | pathogenic | Mucopolysaccharidosis, MPS-II | criteria provided, single submitter | clinical testing | ||
Genome- |
RCV000180473 | SCV002014467 | pathogenic | Mucopolysaccharidosis, MPS-II | 2021-09-05 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV000180473 | SCV003825334 | pathogenic | Mucopolysaccharidosis, MPS-II | 2022-10-13 | criteria provided, single submitter | clinical testing | |
Foundation for Research in Genetics and Endocrinology, |
RCV000180473 | SCV003915848 | pathogenic | Mucopolysaccharidosis, MPS-II | 2023-03-22 | criteria provided, single submitter | clinical testing | A hemizygous variation in exon 9 of the IDS gene detected. The observed variant c.1403G>A has not been reported in the 1000 genomes databases. The in silico prediction is damaging by SIFT, PROVEAN, Polyphen2 and MutationTaster. In summary, the variant meets our criteria to be classified as pathogenic. |
Labcorp Genetics |
RCV000180473 | SCV004299009 | pathogenic | Mucopolysaccharidosis, MPS-II | 2023-07-25 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant disrupts the p.Arg468 amino acid residue in IDS. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 1284597, 15614569, 28077157, 30639582). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. Experimental studies have shown that this missense change affects IDS function (PMID: 18500569). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on IDS protein function. ClinVar contains an entry for this variant (Variation ID: 10498). This missense change has been observed in individuals with mucopolysaccharidosis II (PMID: 7581397, 9266380, 9875019). This variant is not present in population databases (gnomAD no frequency). This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 468 of the IDS protein (p.Arg468Gln). |
OMIM | RCV000011244 | SCV000031471 | pathogenic | Mucopolysaccharidosis type 2, severe form | 1997-01-01 | no assertion criteria provided | literature only | |
Gene |
RCV000180473 | SCV000999927 | not provided | Mucopolysaccharidosis, MPS-II | no assertion provided | literature only |